The results of including treatment with SGLT2 inhibitors for individuals with CKD stages 3a and 3b with diabetes and the introduction of pre-dialysis for individuals with CKD stages 4 and 5 are shown in Tables 3 (number of cases) and 4 (costs). Here, SLC5A2 is linked to diabetes mellitus.